Spironolactone
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Spironolactone: From Hypertension/Oedema to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Spironolactone is a mineralocorticoid receptor antagonist widely used for hypertension, oedema, heart failure and primary hyperaldosteronism, and is already used off-label for androgen-driven hair conditions such as female pattern hair loss and hirsutism. The TxGNN model predicts it may be effective for Hypotrichosis Simplex of the Scalp, but this prediction is currently supported by 0 clinical trials and 0 publications, and the disease itself is a genetic/structural hair-follicle disorder with no known link to the drug's mechanism.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension, oedema, primary hyperaldosteronism (general clinical knowledge; not captured in this evidence pack — original_indications and Taiwan license data are both empty) |
| Predicted New Indication | Hypotrichosis Simplex of the Scalp |
| TxGNN Prediction Score | 99.26% (rank 7,390) |
| Evidence Level | L5 (model prediction only, no clinical trials or literature found) |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is currently unavailable in the evidence pack (marked as a data gap, DG002 — High severity). Based on general pharmacological knowledge, spironolactone is a mineralocorticoid receptor antagonist that also blocks the androgen receptor and inhibits steroidogenesis, which is why it is used off-label for androgenetic alopecia and hirsutism in women.
However, hypotrichosis simplex of the scalp is an autosomal dominant hair follicle developmental disorder, mainly associated with APCDD1 mutations. It is a structural/developmental condition, not an androgen- or mineralocorticoid-driven process, and there is no established pathological link to spironolactone's mechanism.
The second predicted indication in this pack, congenital hypotrichosis with milia (score 99.04%, rank 9,158), shows the same pattern — another rare genetic hair/skin disorder (associated with genes such as LIPH) with no known androgen or mineralocorticoid pathway involvement. The fact that both top predictions fall into the same "hair loss/hypotrichosis" disease cluster suggests the TxGNN score is likely driven by embedding proximity between "drug ↔ hair loss" concepts generally, rather than by a specific, verified mechanistic connection to these particular genetic disorders. This is a plausible but unverified hypothesis, and should be treated as speculative rather than confirmed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is based solely on the TxGNN model score (L5, no supporting clinical trials or literature), and the target disease is a genetic/structural hair follicle disorder with no established mechanistic link to spironolactone's antimineralocorticoid/antiandrogen activity. The apparent similarity to a second, unrelated hypotrichosis prediction further suggests the score may reflect disease-cluster proximity in the model's embedding space rather than a real pharmacological signal.
To proceed, the following is needed:
- TFDA package insert (warnings/contraindications) — currently blocking (DG001)
- Confirmed mechanism of action data from DrugBank (DG002)
- Targeted literature/preclinical search on APCDD1-related hypotrichosis and any androgen/mineralocorticoid pathway involvement
- Dermatology/genetics expert review of biological plausibility before advancing past S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.